The findings challenge the conventional view that daytime sleepiness is always a result of insufficient sleep, poor sleep hygiene or classic sleep disorders.

In 2025, atopic dermatitis care evolved with new treatments, prioritizing holistic methods and personalized strategies for improved patient outcomes.

Researchers used nanoparticle technology to encapsulate paclitaxel and target bladder tumors more effectively. Early results demonstrate tumor elimination and minimal side effects.

Kyverna’s investigational CAR-T therapy, mivocabtagene autoleucel (miv-cel) showed clinically meaningful mobility improvements in most stiff-person syndrome patients, prompting the company to plan an FDA BLA submission in 2026.

The new radiotracer takes advantage of two biological targets linked to fibrotic and inflammatory processes in the lung: fibroblast activation protein and integrin receptors.

Falls among older adults with visual impairment are strongly linked to modifiable home hazards—especially broken flooring and tripping risks—while fall risk remains relatively low in hazard-free homes.

Trial results presented at the annual meeting of the American Society of Hematology showed decided advantages of Hympavzi (mastacimab) over on-demand treatment with bypassing agents.

Despite widespread awareness of shingles risk factors, fewer than one-third of U.S. primary care physicians are fully aware of current ACIP shingles vaccine recommendations, highlighting the need for improved education and implementation.

The top stories out of the AAD annual meeting highlight how dermatology care is evolving.